Newcells Biotech

Project leader

Company presentation

Newcells Biotech are experts in the production of induced pluripotent stem cells (iPSCs), their differentiation into a wide range of reliable and reproducible cell and tissue types and the development of cell-based assays.

Our focus is to provide customers engaged in drug discovery, pre-clinical development and disease mechanism investigation, with the best quality cells and services.

Company Background

Newcells Biotech, founded in 2014 as a spin out biotechnology company from Newcastle University, set out with the aim of providing innovative solutions to accelerate the drug discovery process in the pharmaceutical industry.

It was founded on the technology and expertise of one of the UK’s most experienced centres of stem cell biology based in Newcastle upon Tyne, UK. The team behind Newcells was one of the first to use iPSC (induced pluripotent stem cells) technology in the UK and is at the core of one of the main centres of reprogramming in Europe, which is on course to create 1,500 iPSC cell lines over the next 2.5 years.

Newcells is located close to one of the largest research-intensive medical university and hospital complexes in the UK giving us access to cell biologists and clinicians that understand cell differentiation and disease phenotypes

Newcells Biotech can source tissues from patients, generate iPSC from these, and convert the pluripotent cells into the somatic cell types required to model the disease. We have existing primary cell based assays for nephrotoxicity and transporter studies as well as assay development projects using iPSC technology for skin metabolism and retinal toxicity. We provide our services to drug discovery, toxicity and DMPK teams in Europe, USA and Japan.

StemBANCC receives research funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115439, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author's views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.